Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that leading independent proxy voting and corporate governance advisory firm Glass, Lewis & Co. LLC (“Glass Lewis”) published a report on June 12, 2025 recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company’s nominees for the Board of Directors (the “Board”) at the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the “Meeting”).

Glass Lewis is the second independent proxy advisory firm to recommend voting for the Company’s nominees for the Board, following a similar recommendation issued by Institutional Shareholder Services (“ISS”) on May 30, 2025.

Vote for the Highly Qualified MediPharm Nominees

MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company’s nominees and resolutions. All votes must be received no later than 3:00 p.m. (Eastern time) on Friday, June 13, 2025.

To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting www.medipharmlabsagm.com.

You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company’s nominees.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.